• Net sales amounted to SEK 0 thousand (0)
• Loss before tax amounted to SEK -18,934 thousand (-13,912)
• Earnings per share before dilution amounted to SEK -0.92 (-0.73)
• Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971)
• Cash flow from investing activities amounted to SEK -47,541 thousand (-25,188)
• Cash and cash equivalents at the end of the period amount-ed to SEK 196,212 thousand (292,265)

Amounts in parentheses refer to the year-earlier period.

Significant events during the quarter

• In January, the FDA announced that the application for market approval of Dasynoc had been accepted for a full review.
• In February, the company announced that it had hired Anna-Karin Ekberg as Global Head of Marketing and Sales. Anna-Karin took office on March 15, 2022 and is now part of the company’s management group.
• In February, it was announced that Bristol Myers Squibb had filed a lawsuit against Xspray Pharma in the US claiming pa-tent infringement in relation to the submission of Xspray Pharma’s 505(b)(2) New Drug Application to the FDA.

“Xspray Pharma is in an intense period, with a focus on building up the company, commercialization, the project portfolio, and production capacity. It is intensive, rewarding work for all of us,” says Per Andersson, CEO.